MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why EYPT Stock advanced +0.69% Today — RQD Quant Desk Flash
$0.38 +0.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.38
EyePoint Inc. (EYPT) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $32.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.38 (-0.07%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-7.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EYPT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY EYPT SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (34% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (21% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$3.40-12.1% Next Q
46
Q2 (-2Q)Grade D$2.99-86.6% Next Q
43
Q3 (-1Q)Grade D$0.40-5% Next Q
41
CurrentGrade D-$0.38-7.8% Hist 90D α
38
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a EYPT Turnaround Squeeze
While EYPT currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.21) and Max Pain ($0.40) forces dealer call-delta covering toward $20.07.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $EYPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EYPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why EYPT Stock advanced +0.69% Today — RQD Quant Desk Flash
EyePoint Inc. (EYPT) advanced +0.69% to $0.38, trading at 2% of its 52-week range ($0.34 – $19.11). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.34 – $19.11) with RSI-14 at 15.7 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.38 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live EYPT Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EYPT)
- ✓Walkthrough of EYPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
EYPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -97.12%▼ DESCENDING CHANNEL
2026-10-30O $0.37H $0.38L $0.34C $0.38VOL 6.10M
RES: $12.74SUP: $-2.52SMA50: $3.21SMA200: $10.98
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
EYPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -27.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on EYPT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for EYPT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EYPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EYPT)
Health Care Rank #724 of 1016
⚔️ PRPO vs EYPT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (EYPT vs. PRPO, RPID, HBIO, BNGO)
Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, EyePoint Inc. (EYPT) ranks #724 by composite RQD confidence (38/100, grade D-) and #793 by equity capitalization ($32.8M). Within this direct 5-issuer industry benchmark cohort, EYPT leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with EYPT at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EYPT
ACTIVE
EyePoint Inc. | D- | 38/100 | — | — | -35.0% | +0.69% | $32.8M | Benchmark Subject |
| PRPO Precipio Inc. | D- | 38/100 | — | 44.2% | -7.9% | +3.59% | $34.6M | /prpo-vs-eypt → |
| RPID Rapid Micro Biosystems Inc. (Class A) | D | 47/100 | — | — | -35.0% | -1.37% | $39.6M | /rpid-vs-eypt → |
| HBIO Harvard Bioscience Inc. | D | 44/100 | — | 57.7% | -35.0% | +4.51% | $40.1M | /hbio-vs-eypt → |
| BNGO Bionano Genomics Inc. | D- | 36/100 | — | 46.3% | -35.0% | -0.41% | $16.8M | /bngo-vs-eypt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001314102In its most recent audited fiscal period (FY2025, filed 2025-12-31), EyePoint Inc. (EYPT) reported GAAP revenue of $31.4M (-27.5% vs. FY2024 revenue of $43.3M , and -31.8% cumulative change since FY2023) , GAAP net income of -$232.0M, operating cash flow of -$240.1M, and free cash flow of -$243.4M (-86.8% YoY). On the balance sheet, EYPT closed FY2025 with $364.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $31.4M | -$232.0M | -$240.1M | -$243.4M | $364.0M | — |
| FY2024 (FY) | 2024-12-31 | $43.3M | -$130.9M | -$126.2M | -$130.3M | $418.5M | — |
| FY2023 (FY) | 2023-12-31 | $46.0M | -$70.8M | $1.9M | $1.9M | — | — |
3. EYPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs EYPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, EyePoint Inc. (NASDAQ: EYPT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.38 (+0.69% 1D, market cap $32.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EYPT ranks #724 in composite RQD confidence.
How does EYPT compare to PRPO and RPID in the Health Care sector?
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), EYPT carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PRPO (Precipio Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -7.9%, cap $34.6M) and RPID (Rapid Micro Biosystems Inc. (Class A)) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $39.6M). Among the 5-stock peer group, EYPT leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for EYPT?
Per EYPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001314102), EyePoint Inc. generated $31.4M in revenue (-27.5% YoY), -$232.0M in net income, and -$243.4M in free cash flow against $364.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is EYPT trading relative to its 50-day, 200-day, and 52-week technical levels?
EYPT last traded at $0.38 (+0.69% on volume of 6,601,742 shares), positioning the stock -88.16% below its 50-day simple moving average ($3.21) and -96.54% below its 200-day simple moving average ($10.98). Across its 52-week range of $0.34 to $19.11, EYPT sits at the 0.2% percentile with a 14-day RSI of 15.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.43).
EYPT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is EYPT stock moving today?
Why EYPT Stock advanced +0.69% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.